Association Between Osteoprotegerin G1181C and T245G Polymorphisms and Diabetic Charcot Neuroarthropathy

OBJECTIVE Charcot neuroarthropathy is a disabling complication of diabetes. Although its pathogenesis remains unknown, we suppose that genetics may play a relevant role. RESEARCH DESIGN AND METHODS We performed a case-control study with 59 subjects with diabetic Charcot neuroarthropathy (Ch group), 41 with diabetic neuropathy without Charcot neuroarthropathy (ND group), and 103 healthy control subjects (H group) to evaluate the impact of two single nucleotide polymorphisms (SNPs) of the osteoprotegerin gene (G1181C and T245G) on the risk of Charcot neuroarthropathy. RESULTS Regarding the SNPs of G1181C, we found a significant linkage between the G allele and Charcot neuroarthropathy (Ch vs. ND, odds ratio [OR] 2.32 [95% CI 1.3–4.1], P = 0.006; Ch vs. H, 2.10 [1.3–3.3], P = 0.002; and ND vs. H, 0.90 [0.7–1.9], P = 0.452); similarly, we found a linkage with the G allele of T245G (Ch vs. ND, 6.25 [2.2–19.7], P < 0.001; Ch vs. H, 3.56 [1.9–6.7], P = 0.001; and ND vs. H, 0.54 [0.6–5.7], P = 0.304), supporting a protective role for the allele C and T, respectively. For this reason we investigated the frequency of the protective double homozygosis CC + TT (7% in Ch) that was significantly lower in Ch compared with H (0.18 [0.06–0.5], P = 0.002) and with ND (0.17 [0.05–0.58], P = 0.006), whereas there was no difference between H and ND (1.05 [0.43–2.0], P = 0.468). In a multivariate logistic backward regression model, only weight and the lack of CC and TT genotypes were independently associated with the presence of Charcot neuroarthropathy. CONCLUSIONS This is the first study that shows an association between genetic regulation of bone remodeling and Charcot neuroarthropathy.

[1]  E. Weledji,et al.  The Diabetic Foot , 2015 .

[2]  Allen H. Hamdan,et al.  Management of diabetic foot problems. , 2010, Journal of vascular surgery.

[3]  K. Weiss,et al.  Charcot arthropathy risk elevation in the obese diabetic population. , 2008, The American journal of medicine.

[4]  P. Tonin,et al.  Diabetes and osteoporosis , 2008, Aging clinical and experimental research.

[5]  E. Rahme,et al.  Osteoporosis among patients with type 1 and type 2 diabetes. , 2008, Diabetes & metabolism.

[6]  Kari Stefansson,et al.  Multiple genetic loci for bone mineral density and fractures. , 2008, The New England journal of medicine.

[7]  M. Edmonds,et al.  Increased osteoclastic activity in acute Charcot’s osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand , 2008, Diabetologia.

[8]  S. Ku,et al.  Association between osteoprotegerin (OPG), receptor activator of nuclear factor-&kgr;B (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women , 2007, Menopause.

[9]  Laura Herrero,et al.  Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.

[10]  A. Goldfine,et al.  Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.

[11]  Kejun Liu,et al.  PowerMarker: an integrated analysis environment for genetic marker analysis , 2005, Bioinform..

[12]  P. Collin‐Osdoby Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin , 2004, Circulation research.

[13]  Y. Ramot,et al.  The diabetic Charcot foot. , 2004, The Israel Medical Association journal : IMAJ.

[14]  G. Rümenapf,et al.  Diabetische neuropathische Osteoarthropathie (Charcot-Fuß) , 2003 .

[15]  Kevin J. Tracey,et al.  The inflammatory reflex , 2002, Nature.

[16]  C. Marcocci,et al.  Biochemical and ultrasound tests for early diagnosis of active neuro-osteoarthropathy (NOA) of the diabetic foot. , 2002, Diabetes research and clinical practice.

[17]  P. Hudler,et al.  Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[18]  R. Jenkins,et al.  Charcot neuroarthropathy in diabetes mellitus , 2002, Diabetologia.

[19]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[20]  M. Edmonds Progress in care of the diabetic foot , 1999, The Lancet.

[21]  D. Armstrong,et al.  Is Charcot arthropathy a late sequela of osteoporosis in patients with diabetes mellitus? , 1998, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[22]  A. Veves,et al.  The Prediction of Diabetic Neuropathic Foot Ulceration Using Vibration Perception Thresholds: A prospective study , 1994, Diabetes Care.

[23]  J. Adams,et al.  Radiographic Abnormalities in the Feet of Patients With Diabetic Neuropathy , 1994, Diabetes Care.

[24]  P. Sönksen,et al.  A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population , 1993, Diabetologia.

[25]  A. Vinik,et al.  Diagnosis and management of diabetic autonomic neuropathy , 2003, Comprehensive therapy.

[26]  S. Sinha,et al.  Neuro-arthropathy (Charcot joints) in diabetes mellitus (clinical study of 101 cases). , 1972, Medicine.